MDNN: PTSD From Cancer, HCV/HIV Co-infection Care, C. difficile From Antibiotics, and Juluca's Approval

Stay updated on the biggest headlines with MDNN from November 24, 2017.

Hi, I’m Jenna Payesko, and this is MD Magazine News Network - it’s clinical news for connected physicians.

About 20% of patients with cancer experience post-traumatic stress disorder within months of their diagnosis, and many of those patients continue to suffer from the condition in the years to come. In a new study, researchers found that 33% of cancer patients diagnosed with PTSD within 6 months of their cancer discovery were still experiencing persistent symptoms of the psychiatric condition 4 years later.

A recently published study showed that direct-acting antivirals for patients with hepatitis C still deliver consistent sustained virologic response rates to HCV and HIV co-infected patients. Researchers from the University of California at Los Angeles reported that both mono-infected and co-infected patients with hepatitis C posted SVR rates of at least 93%. HCV and HIV co-infected patients were previously identified by the FDA as a specific population with unmet medical needs.

Community-associated Clostridium difficile infections are still commonly caused by antibiotics, according to collected research from the CDC. About 82% of patients researched in the 10 study-participating states reported at least 1 instance of outpatient medical care in the 12 weeks prior to their C. difficile infection. Another 62% of subjects were exposed to antibiotics in the 12 weeks prior to their infection, suggesting that there is a need for improved outpatient prescribing.

The FDA has approved Juluca, the first-ever 2-drug regimen for adult patients with HIV. The fixed-dose tablet therapy contains 2 previously approved drugs, dolutegravir (ViiV Healthcare) and rilprivirine (Janssen) and was shown to continue viral suppression comparable to current HIV drugs in 2 clinical trials. The treatment improves on the current rate of standard HIV treatment combinations, which commonly contain 3 or more drugs.

And now, please enjoy expert insights into biologic agents in psoriatic arthritis from Allan Gibofsky, MD.

For more clinical insights direct from the experts, visit mdmag.com/insights.

I’m Jenna Payesko for MDNN, thank for you watching.